Table 1.
Baseline methylation and cytology results
| A. | ||||
|---|---|---|---|---|
| Total cohort | ||||
| Methylation | Cytology | |||
| − | + | Total | ||
| MM− | 543 | 122 | 665 | |
| MM+ | 179 | 196 | 375 | |
| Total | 722 | 318 | 1040 | |
| B. | ||||
|---|---|---|---|---|
| Women with cancer in follow‐up | ||||
| Methylation | Cytology | |||
| − | + | Total | ||
| MM− | 11 | 0 | 11 | |
| MM+ | 10 | 14 | 24 | |
| Total | 21 | 14 | 35 | |
| Women with cancer in follow‐up | ||||
|---|---|---|---|---|
| Methylation | Cytology | |||
| − | + | Total | ||
| MM− | 532 | 122 | 654 | |
| MM+ | 169 | 182 | 351 | |
| total | 701 | 304 | 1005 | |
Number of women positive or negative for methylation and cytology; (A) overall and (B) stratified for outcome (i.e., with or without cervical cancer diagnosis during 14‐years of follow‐up).
Abbreviations: MM− = negative for FAM19A4/mir124‐2 methylation; MM+ = positive for FAM19A4/mir124‐2 methylation; − = normal cytology; + = cytology‐positive (≥ borderline dyskaryosis or ASC‐US).